Amifampridine (Firdapse), with the English name "amifampridine" and another alias "amifampridine phosphate", is a specific drug for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and is widely used in many countries around the world.
Precautions for Medication Use of Amifampridine (Firdapse)
Special populations such as pregnant women, lactating women, children, the elderly, and patients with renal insufficiency need to be more cautious when using amifampridine.
Pregnant and Lactating Women
There is no data on the association between amifampridine use in pregnant women and developmental risks, so pregnant women should avoid using it.
Currently, there is no data on the impact of amifampridine on breast milk. It is recommended that lactating women consult a doctor before using amifampridine and make a decision after weighing the pros and cons.
Children
The safety and efficacy of amifampridine in pediatric patients have been confirmed in those aged 6 years and above. For younger pediatric patients, further research is needed to verify its safety and efficacy.
Elderly Patients
For elderly patients, dose selection should be cautious. Due to potential issues such as decreased liver and kidney function in elderly patients, it is generally recommended to start using the drug at the lower end of the dose range and adjust the dose gradually based on the patient's condition.
Patients with Renal Insufficiency
Since amifampridine is mainly excreted through the kidneys, renal insufficiency may lead to drug accumulation in the body and increase the risk of adverse reactions. For such patients, amifampridine should be initiated at the lowest recommended daily initial dose, and adverse reactions should be closely monitored. The dose should be adjusted or the drug discontinued according to the patient's renal function status.
Is Amifampridine (Firdapse) Covered by Medical Insurance?
Amifampridine (Firdapse) has not yet been included in China's medical insurance system. Patients need to purchase it through formal medical service institutions.
Current Status of Medical Insurance Coverage
Amifampridine has not been incorporated into China's medical insurance system. For LEMS patients who require amifampridine for treatment, the drug cost will impose a considerable economic burden. Patients can purchase the drug through formal medical service institutions and bear all the expenses themselves.
Purchase Recommendations
Patients can pay close attention to updates on medical insurance policies to stay informed about the latest progress of amifampridine's medical insurance application.
Proactively communicate with medical institutions and doctors to seek support such as financial assistance or drug donations.
Arrange family financial expenditures reasonably to continuously purchase amifampridine for treatment.
During the purchase and use of the drug, patients should pay attention to updates on medical insurance policies, arrange family financial expenditures properly, and take the medication in accordance with the doctor's guidance.
